Fibroblast growth factor-23 (FGF-23) is associated with an elevated risk of death and of cardiovascular (CV) events in patients with chronic kidney disease (CKD), according to findings published in the Journal of the American Society of Nephrology (2011;22:1913-1922).
In a study of 1,099 stored plasma samples from patients with advanced CKD, researchers observed that, compared with patients in the lowest FGF-23 quartile, each subsequent quartile was associated with a progressively higher death risk.
The two highest quartiles were associated with an elevated risk for CV events and initiation of dialysis.
Enjoying our content?
Thanks for visiting Renal & Urology News. We hope you’re enjoying the latest clinical news, full-length features, case studies, and more.
You’ve viewed {{metering-count}} of {{metering-total}} articles this month. If you wish to read unlimited content, please log in or register below. Registration is free.
{{login-button}} {{register-button}}
Log in to continue reading this article.
Don’t miss out on today’s top content on Renal & Urology News. Register for free and gain unlimited access to:
- Clinical News, with personalized daily picks for you
- Case Studies
- Conference Coverage
- Full-Length Features
- Drug Monographs
- And More
{{login-button}} {{register-button}}
Want to read more?
Please login or register first to view this content.